Abstract
Purpose :
To investigate the increase in intraocular pressure (IOP) following intravitreal dexamethasone implant.
Methods :
The electronic medical records of a large single-specialty retina practice, Retina Associates of Cleveland, Inc., was queried for patients administered intravitreal dexamethasone implant(s). The Institutional Review Board granted this study a waiver of authorization. IOP was measured at the initial, subsequent, and final visit using Goldmann applanation or tonopen. The change in eye pressure was analyzed in comparison to the baseline IOP. The data analyzation was done on a stratified response basis, comparing stratified change of 5mmHg and 10mmHg, as well as exceeding the 21mmHg mark in IOP for those whose pressure was below that threshold prior to treatment.
Results :
There were 165 participants included in this study. Overall, 53 (31.2%) patients had an IOP increase from baseline that is greater than 5mmHg and 13 (7.9%) with an increase that is greater than 10mmHg. Overall, 161 (97.5%) of the patients had IOP at or below 21mmHg at the first visit. Of those, 38 (23.6%) had eye pressure that exceeded 21mmHg following at least one intravitreal dexamethasone implant.
Conclusions :
Intravitreal dexamethasone implant has some incidence of increased IOP among participants that were administered the treatment in this study. Of the 165 patients, 31.2% showed an increase of at least 5mmHg and 7.9% showed an increase of 10mmHg or greater. Additionally, 23.6% had their pressure increase to above 21mmHg following the treatment.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.